Contact
searchSearch
HMP Global

October 2013 - FRMC

Department
Xtandi® (enzalutamide) - Oral Drug to Treat Castration-Resistant Prostate Cancer
10/23/2013
The FDA approved Xtandi® (enzalutamide) in August 2012 to treat patients with metastatic castration-resistant prostate cancer who previously failed treatment with docetaxel. The oral drug, marketed by Astellas Pharma, Inc. and Medivation,...
The FDA approved Xtandi® (enzalutamide) in August 2012 to treat patients with metastatic castration-resistant prostate cancer who previously failed treatment with docetaxel. The oral drug, marketed by Astellas Pharma, Inc. and Medivation,...
The FDA approved Xtandi®...
10/23/2013
First Report Managed Care
Efficacy of Long-Term Opioid Treatment
10/23/2013
Tim Casey
Patients with chronic non-cancer pain maintained reductions in pain for at least 6 months, according to a review of randomized, controlled trials, single-arm, open-label trials, open-label extension trials, and epidemiologic trials.
Patients with chronic non-cancer pain maintained reductions in pain for at least 6 months, according to a review of randomized, controlled trials, single-arm, open-label trials, open-label extension trials, and epidemiologic trials.
Patients with chronic non-cancer...
10/23/2013
First Report Managed Care
Department
Lubiprostone to Treat Non-Cancer Pain and Opioid-Induced Constipation
10/23/2013
Tim Casey
Patients with chronic non-cancer pain and opioid-induced constipation who took lubiprostone did not have an affect on opioid-induced analgesia.
Patients with chronic non-cancer pain and opioid-induced constipation who took lubiprostone did not have an affect on opioid-induced analgesia.
Patients with chronic non-cancer...
10/23/2013
First Report Managed Care
Breakthrough Pain and Cancer Costs
10/23/2013
Tim Casey
Peoople with cancer and controlled, persistent pain had statistically significant higher mean unadjusted all-cause pharmacy costs if they had breakthrough pain. 
Peoople with cancer and controlled, persistent pain had statistically significant higher mean unadjusted all-cause pharmacy costs if they had breakthrough pain. 
Peoople with cancer and...
10/23/2013
First Report Managed Care
Managing Breakthrough Pain
10/23/2013
Tim Casey
At the AAPM meeting, healthcare professionals discussed issues related to cancer-related pain during a satellite symposium titled Managing Breakthrough Pain Across the Provider Continuum. 
At the AAPM meeting, healthcare professionals discussed issues related to cancer-related pain during a satellite symposium titled Managing Breakthrough Pain Across the Provider Continuum. 
At the AAPM meeting, healthcare...
10/23/2013
First Report Managed Care
Conference Insider
Assessing the Misuse and Abuse of Opioids
10/23/2013
Tim Casey
Five years ago, David Fishbain, MD, and co-authors published an article in Pain Medicine that examined issues related to opioids.
Five years ago, David Fishbain, MD, and co-authors published an article in Pain Medicine that examined issues related to opioids.
Five years ago, David Fishbain,...
10/23/2013
First Report Managed Care
AUA Guidelines for Castrate-Resistant Prostate Cancer
10/23/2013
Tim Casey
To help clinicians treat patients with castrate-resistant prostate cancer, the AUA released guidelines at its annual meeting to decide what options are best for numerous sub-types of the disease. 
To help clinicians treat patients with castrate-resistant prostate cancer, the AUA released guidelines at its annual meeting to decide what options are best for numerous sub-types of the disease. 
To help clinicians treat...
10/23/2013
First Report Managed Care
Complications Associated with Surgery for Bladder Cancer
10/23/2013
Tim Casey
San Diego—An interim analysis of a prospective, randomized trial found that there was no significant difference in 90-day complications after patients with bladder cancer underwent robotic radical cystectomy with extracorporeal urinary...
San Diego—An interim analysis of a prospective, randomized trial found that there was no significant difference in 90-day complications after patients with bladder cancer underwent robotic radical cystectomy with extracorporeal urinary...
San Diego—An interim analysis of...
10/23/2013
First Report Managed Care
Treatment with Canagliflozin for 52 Weeks
10/23/2013
Tim Casey
San Diego—After 52 weeks of treatment, patients with type 2 diabetes who received 100 mg or 300 mg of canagliflozin had reductions in hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), body weight and systolic blood pressure, according to...
San Diego—After 52 weeks of treatment, patients with type 2 diabetes who received 100 mg or 300 mg of canagliflozin had reductions in hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), body weight and systolic blood pressure, according to...
San Diego—After 52 weeks of...
10/23/2013
First Report Managed Care
Empagliflozin for Patients with Type 2 Diabetes and Hypertension
10/23/2013
Tim Casey
San Diego—Patients with type 2 diabetes and hypertension who received 10 mg or 25 mg of empagliflozin once daily for 12 weeks had significant and clinically meaningful reductions in systolic and diastolic blood pressure, according to a phase...
San Diego—Patients with type 2 diabetes and hypertension who received 10 mg or 25 mg of empagliflozin once daily for 12 weeks had significant and clinically meaningful reductions in systolic and diastolic blood pressure, according to a phase...
San Diego—Patients with type 2...
10/23/2013
First Report Managed Care
Repeat Lipid Testing in Patients with Coronary Heart Disease
10/23/2013
Kevin L. Carter
Based on Adult Treatment Panel III guidelines, it is common current practice to suggest annual lipid testing in patients with coronary heart disease (CHD). Those with abnormal lipid levels are suggested to receive intensified treatment. For...
Based on Adult Treatment Panel III guidelines, it is common current practice to suggest annual lipid testing in patients with coronary heart disease (CHD). Those with abnormal lipid levels are suggested to receive intensified treatment. For...
Based on Adult Treatment Panel...
10/23/2013
First Report Managed Care
News Connection
US Health Improves but Lags behind Other Wealthy Countries
10/23/2013
Jill Sederstorm
Population health in the United States has improved, but the improvements have not kept pace with other wealthy nations, according to a new study that assessed the state of United States health from 1990 to 2010. The study measured the burden...
Population health in the United States has improved, but the improvements have not kept pace with other wealthy nations, according to a new study that assessed the state of United States health from 1990 to 2010. The study measured the burden...
Population health in the United...
10/23/2013
First Report Managed Care
News Connection
Some States Still Debating Expanding Medicaid
10/23/2013
Tori Socha
One of the primary goals of the Patient Protection and Affordable Care Act (ACA) is to reduce the number of uninsured Americans. To achieve this, the act provides for affordable options for coverage including Medicaid and Health Insurance...
One of the primary goals of the Patient Protection and Affordable Care Act (ACA) is to reduce the number of uninsured Americans. To achieve this, the act provides for affordable options for coverage including Medicaid and Health Insurance...
One of the primary goals of the...
10/23/2013
First Report Managed Care
News Connection
Integrated Delivery Systems for Hospital Inpatient Surgeries
10/23/2013
Jill Sederstorm
Integrated delivery systems (lDSs) have been shown to improve quality and lower costs in ambulatory care settings.
Integrated delivery systems (lDSs) have been shown to improve quality and lower costs in ambulatory care settings.
Integrated delivery systems...
10/23/2013
First Report Managed Care
PCI for Prevention of Future Cardiac Events
10/23/2013
Tori Socha
Percutaneous coronary intervention (PCI) is an effective treatment for patients with acute ST-segment elevation myocardial infarction (STEMI). PCI restores blood flow to the coronary artery that is deemed to be causing the myocardial...
Percutaneous coronary intervention (PCI) is an effective treatment for patients with acute ST-segment elevation myocardial infarction (STEMI). PCI restores blood flow to the coronary artery that is deemed to be causing the myocardial...
Percutaneous coronary...
10/23/2013
First Report Managed Care
News Connection
Pretreatment with Prasugrel Associated with Increase in Major Bleeding Complications
10/23/2013
Tori Socha
P2Y12 receptor antagonists are effective in patients with non–ST-segment elevation (NSTE) acute coronary syndromes. A loading dose of clopidogrel is required in patients undergoing percutaneous coronary intervention (PCI); however,...
P2Y12 receptor antagonists are effective in patients with non–ST-segment elevation (NSTE) acute coronary syndromes. A loading dose of clopidogrel is required in patients undergoing percutaneous coronary intervention (PCI); however,...
P2Y12 receptor antagonists are...
10/23/2013
First Report Managed Care
Pazopanib versus Sunitinib for Metastatic Renal-Cell Carcinoma
10/23/2013
Mary Beth Nierengarten
Results of a phase 3, randomized, open-label trial demonstrate the noninferiority in progression-free survival of pazopanib compared with sunitinib in patients with metastatic renal-cell carcinoma.
Results of a phase 3, randomized, open-label trial demonstrate the noninferiority in progression-free survival of pazopanib compared with sunitinib in patients with metastatic renal-cell carcinoma.
Results of a phase 3,...
10/23/2013
First Report Managed Care
Kaiser Permanente Northern California Hypertension Control Program
10/23/2013
Tori Socha
Hypertension, a major contributor to cardiovascular disease, affects 29% of the adult population in the United States (n=65 million). Effective therapies to control hypertension have been available for >50 years; however, from 2001 to...
Hypertension, a major contributor to cardiovascular disease, affects 29% of the adult population in the United States (n=65 million). Effective therapies to control hypertension have been available for >50 years; however, from 2001 to...
Hypertension, a major...
10/23/2013
First Report Managed Care
News Connection
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
10/23/2013
Kevin L. Carter
Vedolizumab, a humanized monoclonal antibody, selectively blocks gut lymphocyte trafficking without interfering with trafficking to the central nervous system.
Vedolizumab, a humanized monoclonal antibody, selectively blocks gut lymphocyte trafficking without interfering with trafficking to the central nervous system.
Vedolizumab, a humanized...
10/23/2013
First Report Managed Care
Early Surgery versus Watchful Waiting for Mitral Valve Regurgitation
10/23/2013
Tori Socha
The vast majority of patients with degenerative mitral regurgitation have symptoms improved and normal life expectancy restored with surgical intervention. In patients without American College of Cardiology (ACC)/American Heart Association...
The vast majority of patients with degenerative mitral regurgitation have symptoms improved and normal life expectancy restored with surgical intervention. In patients without American College of Cardiology (ACC)/American Heart Association...
The vast majority of patients...
10/23/2013
First Report Managed Care
Intense Lifestyle Intervention in Type 2 Diabetes
10/23/2013
Tori Socha
It has been well documented that overweight or obese patients with type 2 diabetes benefit from weight loss, with numerous short-term studies demonstrating such benefits as improved glycemic control, reduction of cardiovascular disease risk...
It has been well documented that overweight or obese patients with type 2 diabetes benefit from weight loss, with numerous short-term studies demonstrating such benefits as improved glycemic control, reduction of cardiovascular disease risk...
It has been well documented that...
10/23/2013
First Report Managed Care
Use of ADT Associated with Risk of AKI
10/23/2013
Tori Socha
Patients with advanced prostate cancer are often treated with androgen deprivation therapy (ADT), a therapy that is also increasingly being used in patients with less severe disease. Studies have demonstrated that ADT provides beneficial...
Patients with advanced prostate cancer are often treated with androgen deprivation therapy (ADT), a therapy that is also increasingly being used in patients with less severe disease. Studies have demonstrated that ADT provides beneficial...
Patients with advanced prostate...
10/23/2013
First Report Managed Care
Radium-223 Improves Overall Survival in Prostate Cancer
10/23/2013
Mary Mihalovic
In men with castration-resistant prostate cancer and bone metastases, the use of the targeted alpha emitter radium-223 dichloride showed enough improvement in overall survival to warrant the trial’s early discontinuation.
In men with castration-resistant prostate cancer and bone metastases, the use of the targeted alpha emitter radium-223 dichloride showed enough improvement in overall survival to warrant the trial’s early discontinuation.
In men with castration-resistant...
10/23/2013
First Report Managed Care
Nivolumab Plus Ipilimumab in Advanced Melanoma
10/23/2013
Kevin L. Carter
There has been increased interest in developing tumor immunity as a treatment strategy for several types of cancer. Immune checkpoint blockade is one approach that has induced regressions in cancer. Ipilimumab, a fully human, IgG1 monoclonal...
There has been increased interest in developing tumor immunity as a treatment strategy for several types of cancer. Immune checkpoint blockade is one approach that has induced regressions in cancer. Ipilimumab, a fully human, IgG1 monoclonal...
There has been increased...
10/23/2013
First Report Managed Care
News Connection
Apixaban Treatment for Acute VTE
10/23/2013
Eileen Koutnik-Fotopoulos
A fixed-dose regimen of apixaban, an oral factor Xa inhibitor, to treat venous thromboembolism (VTE) demonstrated noninferiority to conventional therapy with enoxaparin and warfarin, according to findings from the AMPLIFY (Apixaban for the...
A fixed-dose regimen of apixaban, an oral factor Xa inhibitor, to treat venous thromboembolism (VTE) demonstrated noninferiority to conventional therapy with enoxaparin and warfarin, according to findings from the AMPLIFY (Apixaban for the...
A fixed-dose regimen of...
10/23/2013
First Report Managed Care
Disability Trajectories and Serious Fall Injury
10/23/2013
Tori Socha
Among Medicare beneficiaries, falls account for approximately 10% of emergency department visits and 6% of hospitalizations.
Among Medicare beneficiaries, falls account for approximately 10% of emergency department visits and 6% of hospitalizations.
Among Medicare beneficiaries,...
10/23/2013
First Report Managed Care
Reducing Risk of Stroke in Patients with TIA
10/23/2013
Mary Beth Nierengarten
A recent trial shows that combining clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke among patients with TIA.
A recent trial shows that combining clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke among patients with TIA.
A recent trial shows that...
10/23/2013
First Report Managed Care
News Connection
Estimated Cancer Risk with Use of CT in Pediatrics
10/23/2013
Tori Socha
Over the past 20 years, the use of computed tomography (CT) in pediatrics has been increasing. In 2001, 5% to 11% of the 85 million CT scans performed in the United States were on children. The use of CT has improved diagnostic capabilities,...
Over the past 20 years, the use of computed tomography (CT) in pediatrics has been increasing. In 2001, 5% to 11% of the 85 million CT scans performed in the United States were on children. The use of CT has improved diagnostic capabilities,...
Over the past 20 years, the use...
10/23/2013
First Report Managed Care
RA and Work Loss: Biologic versus DMARD Treatment
10/23/2013
Eileen Koutnik-Fotopoulos
The introduction of biologic tumor necrosis factor inhibitors has improved the treatment of early rheumatoid arthritis (RA), but at a significant cost. These medications have been shown to lead to superior radiological outcomes compared with...
The introduction of biologic tumor necrosis factor inhibitors has improved the treatment of early rheumatoid arthritis (RA), but at a significant cost. These medications have been shown to lead to superior radiological outcomes compared with...
The introduction of biologic...
10/23/2013
First Report Managed Care
News Connection
GAO Report: Self-Referrals Cost Medicare Millions
10/23/2013
Eileen Koutnik-Fotopoulos
A new report, Medicare: Action Needed to Address Higher Use of Anatomic Pathology Services by Providers Who Self-Refer, from the Government Accountability Office (GAO) found a dramatic increase in self-referred anatomic pathology services...
A new report, Medicare: Action Needed to Address Higher Use of Anatomic Pathology Services by Providers Who Self-Refer, from the Government Accountability Office (GAO) found a dramatic increase in self-referred anatomic pathology services...
A new report, Medicare: Action...
10/23/2013
First Report Managed Care
News Connection
Label Changes and New Postmarketing Requirements for Opioids
10/23/2013
Tim Casey
Across the United States, reports have revealed the increasing epidemic of people abusing, misusing, and dying from opioids and other prescription pain medications. The trend has caused government officials, pharmaceutical companies, and...
Across the United States, reports have revealed the increasing epidemic of people abusing, misusing, and dying from opioids and other prescription pain medications. The trend has caused government officials, pharmaceutical companies, and...
Across the United States,...
10/23/2013
First Report Managed Care
News Connection
Telemedicine Becoming More Popular for Nonemergency Care
10/23/2013
Tim Casey
A few years ago, executives at Pepsi Bottling Ventures noticed many of the company’s employees were not visiting doctors on a regular basis. A large percentage of the workers drive trucks and deliver products to 22 bottling and distribution...
A few years ago, executives at Pepsi Bottling Ventures noticed many of the company’s employees were not visiting doctors on a regular basis. A large percentage of the workers drive trucks and deliver products to 22 bottling and distribution...
A few years ago, executives at...
10/23/2013
First Report Managed Care

Behind the Bill

Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care
BEHIND THE BILL
When Agencies Lose Power: How 3 Seismic Shifts are Transforming Pharmaceutical Regulation
05/07/2025
Katie Hayes, MJ
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months,...
05/07/2025
First Report Managed Care
Behind the Bill
The Medicare Paradox, Part 3: Strategic Trade Doesn’t Have to be a Zero-Sum Game
05/07/2025
Katie Hayes, MJ
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve...
05/07/2025
First Report Managed Care

Trending Articles

News
Who Will Benefit Under the Medicare Part D Out-of-Pocket Spending Cap?
02/27/2024
Dean Celia
Starting in 2024, Medicare Part D enrollees could benefit from a cap placed on out-of-pocket drug spending, thanks to a provision in the Inflation Reduction Act of 2022 (IRA).
Starting in 2024, Medicare Part D enrollees could benefit from a cap placed on out-of-pocket drug spending, thanks to a provision in the Inflation Reduction Act of 2022 (IRA).
Starting in 2024, Medicare Part...
02/27/2024
First Report Managed Care
News
The Impact of Inhibitors on Surgical Management in Patients With Hemophilia
04/04/2024
Hannah Musick
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in patients with hemophilia poses challenges for achieving perioperative hemostasis and may result in complications and deviations from the surgical plan, highlighting the need for strategies to address inhibitor...
The development of inhibitors in...
04/04/2024
First Report Managed Care
Conference Coverage
Expanding Pharmacists’ Role in Providing Clinical Care: Addressing Public Health Challenges
05/02/2024
Danielle Sposato
Panelists from various backgrounds discuss the critical role of pharmacists in addressing public health challenges such as HIV/AIDS and advocating for expanded clinical care and reimbursement pathways to improve health outcomes in communities.
Panelists from various backgrounds discuss the critical role of pharmacists in addressing public health challenges such as HIV/AIDS and advocating for expanded clinical care and reimbursement pathways to improve health outcomes in communities.
Panelists from various...
05/02/2024
First Report Managed Care
Managed Care Q&A
Prioritizing Patient Voices in Drug Development and Coverage
05/27/2024
In this interview, guest experts discuss the importance of incorporating patient voices into health care decision-making, highlighting opportunities for collaboration and enhancement in drug development and patient coverage.
In this interview, guest experts discuss the importance of incorporating patient voices into health care decision-making, highlighting opportunities for collaboration and enhancement in drug development and patient coverage.
In this interview, guest experts...
05/27/2024
First Report Managed Care
Blog
The Clash Over Medicare: Key Lawsuits Challenging the IRA’s Drug Negotiation Provisions
07/11/2024
Katie Hayes, MJ
The IRA has spawned a series of lawsuits from pharmaceutical companies. Here, we provide the latest status updates on several of them.
The IRA has spawned a series of lawsuits from pharmaceutical companies. Here, we provide the latest status updates on several of them.
The IRA has spawned a series of...
07/11/2024
First Report Managed Care

October 2013 Volume 10 Issue 10

View Issue Archive
Editorial Correspondence

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use